AAAAAA

   
Results: 1-11 |
Results: 11
Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects
Authors: Dingemanse, J Pedrazzetti, E van Giersbergen, PLM
Citation: J. Dingemanse et al., Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjects, CLIN NEUROP, 24(2), 2001, pp. 82-90
Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
Authors: Descombes, S Bonnet, AM Gasser, UE Thalamas, C Dingemanse, J Arnulf, I Bareille, MP Agid, Y Rascol, O
Citation: S. Descombes et al., Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease, NEUROLOGY, 56(9), 2001, pp. 1239-1242
Investigation of a correlation between monoamine oxidase B and catechol-O-methyltransferase activity in human blood cells
Authors: Dingemanse, J Zurcher, G Kettler, R
Citation: J. Dingemanse et al., Investigation of a correlation between monoamine oxidase B and catechol-O-methyltransferase activity in human blood cells, EUR J PH SC, 12(2), 2000, pp. 159-163
Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects
Authors: Dingemanse, J Bury, M Hussain, Y Van Giersbergen, P
Citation: J. Dingemanse et al., Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjects, DRUG META D, 28(12), 2000, pp. 1411-1416
Issues important for rational COMT inhibition
Authors: Dingemanse, J
Citation: J. Dingemanse, Issues important for rational COMT inhibition, NEUROLOGY, 55, 2000, pp. S24-S27
Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorptionof IS-159, a peptide serotonin 1B/1D-receptor agonist
Authors: Dingemanse, J Soubrouillard, C Paris, J Pisano, P Blin, O
Citation: J. Dingemanse et al., Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorptionof IS-159, a peptide serotonin 1B/1D-receptor agonist, CLIN PHARM, 68(2), 2000, pp. 114-121
The Parkinson's disease symptom inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects
Authors: Hogan, T Grimaldi, R Dingemanse, J Martin, M Lyons, K Koller, W
Citation: T. Hogan et al., The Parkinson's disease symptom inventory (PDSI): a comprehensive and sensitive instrument to measure disease symptoms and treatment side-effects, PARKINS R D, 5(3), 1999, pp. 93-98
Pharmacokinetic-pharmacodynamic investigation of a possible interaction between steady-state temocapril and warfarin in healthy subjects
Authors: Lankhaar, G Eckenberger, P Ouwerkerk, MJA Dingemanse, J
Citation: G. Lankhaar et al., Pharmacokinetic-pharmacodynamic investigation of a possible interaction between steady-state temocapril and warfarin in healthy subjects, CLIN DRUG I, 17(5), 1999, pp. 399-405
Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment
Authors: Dingemanse, J Halabi, A Kleinbloesem, CH Heinig, R Blume, H
Citation: J. Dingemanse et al., Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment, THER DRUG M, 21(3), 1999, pp. 310-316
The effect of age on the pharmacokinetics and pharmacodynamics of midazolam
Authors: Albrecht, S Ihmsen, H Hering, W Geisslinger, G Dingemanse, J Schwilden, H Schuttler, J
Citation: S. Albrecht et al., The effect of age on the pharmacokinetics and pharmacodynamics of midazolam, CLIN PHARM, 65(6), 1999, pp. 630-639
Automated heparin-delivery system to control activated partial thromboplastin time - Evaluation in normal volunteers
Authors: Cannon, CP Dingemanse, J Kleinbloesem, CH Jannett, T Curry, KM Valcke, CP
Citation: Cp. Cannon et al., Automated heparin-delivery system to control activated partial thromboplastin time - Evaluation in normal volunteers, CIRCULATION, 99(6), 1999, pp. 751-756
Risultati: 1-11 |